MorphoSys AG Announces Monjuvi Sales for the First Nine Mont

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to €

Related Keywords

Germany , United States , United Kingdom , Munich , Bayern , Planegg , Thomas Biegi , Julia Neugebauer , Myles Clouston , Jeanette Bressi , Janssen Biotech Inc , Drug Administration , Morphosys Group , Constellation Pharmaceuticals Inc , Janssen Research Development , Morphosys Us Inc , Nasdaq , Exchange Commission , Us Communications , Management Board , Janssen Research , Janssen Biotech , Constellation Pharmaceuticals , Morphosy Annual Report , Morphosys , Nnounces , Monjuvi , Sales , First , Line , Months , Third , Quarter , 021 , Invitation , Pcoming , Conference , Wall , November ,